AbbVie Publishes Results for Ubrelvy (ubrogepant) in P-III Trial for Migraine in ‘The Lancet’

Share this

AbbVie Publishes Results for Ubrelvy (ubrogepant) in P-III Trial for Migraine in ‘The Lancet’


  • The P-III (PRODROME) clinical trial evaluates the safety, efficacy & tolerability of Ubrelvy (100mg) vs PBO in patients (n=518) experiencing 2-8 migraine attacks with moderate-to-severe headache/month. The results from the trials were published in ‘The Lancet’
  • The results from the trial depicted a significant reduction in headache frequency within 24hrs. & 48hrs., with 46% vs 29% & 41% vs 25% of qualifying prodrome events being absent whereas the intensity of headache was also significantly reduced within 24hrs. after 24% vs 14% of qualifying prodrome events
  • Ubrelvy is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) developed for the acute treatment of migraine with or without aura in adults

Ref: PR Newswire | Image: AbbVie

Related News:- Allergan's Ubrelvy (ubrogepant) Receives the US FDA's Approval for Acute Treatment of Migraine with or without Aura in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions